Fatty Liver and Metabolic Health: Understanding MASLD
By Sara Estrin, MD, DABOM
A scan finding is the beginning of a conversation
Seeing “fatty liver” in a report can feel unsettling, especially if nobody has explained what happens next. The most useful response is to clarify what was found, what is still unknown, and how the finding fits the rest of your health.
MASLD stands for metabolic dysfunction-associated steatotic liver disease. It describes a form of liver fat accumulation associated with metabolic health factors. Older records may use NAFLD. MASH is the form that includes inflammation and liver damage; fibrosis means scarring. These terms describe different features, not interchangeable diagnoses. [1]
Write down the exact wording from your report before the visit. It gives you and your clinician a shared starting point without requiring you to decode every abbreviation yourself.
Why metabolic health belongs in the discussion
Fatty liver is more common in people with conditions such as type 2 diabetes, obesity and abnormal cholesterol or triglycerides. It often has few or no symptoms. Evaluation can include history, blood tests and imaging, with further tests in selected cases. [1]
That is why the conversation should extend beyond “Did the scan show fat?” Ask how your glucose, cholesterol, medications and alcohol history affect the interpretation. Bring results from other offices so the discussion is based on the same information.
It is also worth asking who will coordinate follow-up. If one office ordered the scan and another manages your metabolic care, make sure the next step has a clear owner.
The type and stage change the treatment conversation
Research results are most useful when you know who was studied. The 2025 ESSENCE report examined semaglutide 2.4 mg weekly versus placebo in adults with biopsy-defined MASH and stage F2 or F3 fibrosis. Its planned 72-week analysis included the first 800 participants. [2]
MASH resolution without worsening fibrosis occurred in 62.9% with semaglutide versus 34.3% with placebo—an estimated 28.7 percentage-point difference. Fibrosis improvement without worsening MASH occurred in 36.8% versus 22.4%. Gastrointestinal adverse events were more common with semaglutide. [2]
These results help explain why clinicians distinguish simple fat accumulation from MASH and fibrosis. They do not show that everyone with incidental fatty liver will have the same response, or establish reduced liver failure or mortality from this interim report. Treatment eligibility, safety and approved uses require a separate clinical discussion.
A useful way to bring the research into your appointment is: “Does my diagnosis match the population in that trial?” This is a better starting point than assuming the name of a medication settles the question.
Make the follow-up concrete
Ask how liver fat was identified, whether an assessment for scarring is needed, what results will be followed, and when the next review should happen. You can also ask what a reassuring result would look like and what would change the plan.
Before leaving, write down the next test, who will arrange it, and how you will receive the result. If a referral is discussed, ask what question the specialist will help answer.
The goal is to replace an unexplained phrase in a report with an understandable plan. You should know what has been established, what still needs evaluation, and what you are expected to do next.
Sources
Sources checked October 5, 2026. Educational information, not an individual diagnosis or treatment plan.
Make your next step personal
Have questions about your metabolic health? A consultation is a place to discuss your goals and options.
Book a consultation with Dr. Estrin · Explore MM Kitchen
What would you like to learn next?
Suggest a topic for MM Journal. Please keep suggestions general and leave out personal medical information.